Outcomes

Based on available clinical evidence, cagrilintide (including its combination form CagriSema with semaglutide) demonstrates measurable effects on both glycemic control and body weight in adults with type 2 diabetes and obesity.

Primary Efficacy Outcomes

Blood Sugar Control: Multiple Phase 3 studies (REIMAGINE 1 and REIMAGINE 2) have evaluated once-weekly cagrilintide-semaglutide (CagriSema) for glycemic control in adults with type 2 diabetes inadequately controlled on diet and exercise. These completed trials specifically measured blood sugar lowering compared to placebo, individual components (semaglutide or cagrilintide alone), and active comparators like tirzepatide.

Weight Reduction: The same Phase 3 trials assessed body weight changes as a primary outcome. Evidence from systematic reviews and network meta-analyses suggests cagrilintide-containing regimens produce meaningful weight loss in adults with overweight or obesity, though specific numerical results from the individual studies are not detailed in the available abstracts.

Comparative Effectiveness

Recent network meta-analyses have positioned cagrilintide among pharmacologic treatments for adults with overweight or obesity, suggesting it demonstrates competitive efficacy relative to other available therapies. However, the strength of this comparative evidence depends on the number and quality of direct head-to-head studies included in these analyses.

Safety Profile

The completed Phase 3 studies evaluated safety outcomes alongside efficacy measures. While specific adverse event rates are not detailed in available abstracts, the studies specifically assessed both benefits and harms of treatment.

Mechanistic Insights

Preclinical research has identified specific neural pathways in the dorsal vagal complex through which cagrilintide affects energy balance, and cellular targets for its action have been characterized. This mechanistic understanding supports the observed clinical effects on weight and metabolism.

Evidence Limitations

The clinical evidence is primarily derived from Phase 3 studies in adults with type 2 diabetes. Evidence in pediatric populations is limited, with Phase 3 studies in children and adolescents with type 2 diabetes still in planning stages. Additionally, detailed quantitative results from the completed major trials are not yet fully available in peer-reviewed publications.

Note: This information is for educational purposes and should not replace personalized medical advice from healthcare providers.

Cagrilintide

Member access required